There are many challenges related to adolescent vaccinations that practices are currently facing:
• How are our HPV vaccine completion rates?
• Should we promote meningococcal B vaccine universally or just to high-risk patients? Which vaccine should we stock?
• Do patients who already had HPV-4 or HPV-2 need HPV-9?
• How many of our patients have received their 2nd dose of meningococcal ACWY vaccine?
Two new action briefs have been developed with the assistance of the Vaccine Education Center at the Children’s Hospital of Philadelphia to help practices address these issues and provide ideas you can use in your own practice.
Trumenba, Pfizer’s meningococcal B vaccine, is now approved to be administered on a 2-dose schedule, allowing another option for providers. Trumenba can now be administered one of two ways depending on the patient’s risk profile:
- 3-dose schedule at 0, 1-2 and 6 months
- 2-dose schedule at 0 and 6 months
Please see the entire product label for complete product and safety information.
We have received several questions from our members in the last month regarding proper coding and documentation for immunization administration. There are 6 codes that apply:
Under 19, with counseling on each vaccine component:
90460 – first component
90461 – additional component
Under 19, without counseling on each vaccine component OR over 19:
90471 – first injection
90472 – additional injection
90473 – first oral or intranasal administration
90474- additional oral or intranasal administration
In order to bill 90460 and 90461, counseling by a physician or other qualified healthcare professional must be performed on each vaccine component and it must be documented in the medical record.
Please refer to the AAP’s Frequently Asked Question (FAQ) document that helps address vaccine administration coding questions for more information.